In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative
|
|
- Avice Willis
- 6 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (2008) 62, doi: /jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative Deborah C. Draghi 1, Bret M. Benton 2, Kevin M. Krause 2, Clyde Thornsberry 1, Chris Pillar 1 and Daniel F. Sahm 1 * 1 Eurofins Medinet, Inc., Dulles Technology Drive, Suite 200, Herndon, VA, USA; 2 Theravance, Inc., 901 Gateway Boulevard, South San Francisco, CA, USA Received 20 December 2007; returned 21 January 2008; revised 20 February 2008; accepted 27 February 2008 Objectives: Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment of serious infections due to Gram-positive bacteria. The objective of this study was to provide a baseline prospective assessment of its in vitro activity against a large and diverse collection of Gram-positive clinical isolates from Europe and Israel. Methods: Gram-positive clinical isolates, collected between October 2004 and December 2005 from 36 hospital laboratories in 15 countries, were tested by broth microdilution using CLSI methodology. Results: In total, 3206 isolates were collected. Telavancin had potent activity against Staphylococcus aureus and coagulase-negative staphylococci (MIC range to 2 mg/l), independent of resistance to methicillin or to multiple drugs. Telavancin had particularly strong activity against streptococcal isolates (MIC range to 0.5 mg/l), including penicillin-resistant and multiple drug-resistant Streptococcus pneumoniae and erythromycin non-susceptible b-haemolytic and viridans group streptococci. Telavancin also had excellent activity against vancomycin-susceptible enterococci (MIC mg/l), and although its MICs were elevated against VanA strains (Enterococcus faecalis MIC 90 8 mg/l and Enterococcus faecium MIC 90 4 mg/l), its MIC 90 was substantially lower than observed with available glycopeptides. Conclusions: Telavancin has potent in vitro activity against contemporary Gram-positive clinical isolates from diverse geographic areas in Europe and Israel. Keywords: susceptibility tests, Staphylococcus aureus, enterococci, Streptococcus spp. Introduction Drug resistance in Gram-positive pathogens is a continuing worldwide healthcare concern. Telavancin is a novel, investigational lipoglycopeptide that has demonstrated superior in vitro activity, when compared with currently available glycopeptides, against a range of clinically important Gram-positive bacteria including resistant organisms. 1 4 Against methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis, telavancin was shown in several studies to be 2- to 8-fold more potent than vancomycin and 4- to 32-fold more potent than teicoplanin. 2 4 Telavancin also demonstrated activity against vancomycin-resistant enterococci (VRE). 2,4 Telavancin has a unique, multifunctional mechanism of action that appears to be responsible for its more rapid and extensive bactericidal activity observed relative to other available glycopeptides. 5 Like vancomycin, telavancin inhibits peptidoglycan biosynthesis by binding to the D-alanyl-D-alanine termini of peptidoglycan intermediates, thus disrupting late-stage steps in cell wall biosynthesis. In intact MRSA cells, telavancin was 14-fold as active as vancomycin in inhibiting peptidoglycan synthesis [50% inhibitory concentrations (IC 50 ) 0.14 and 2.0 mm, respectively]. 6 Additionally, telavancin interferes with bacterial cell membrane function, an activity not previously observed for glycopeptides. In MRSA cells, telavancin exposure resulted in concentration-dependent membrane depolarization... *Corresponding author. Tel: þ ; Fax: þ ; daniel.sahm@eurofinsmedinet.com # The Author Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 In vitro activity of telavancin against European and Israeli isolates and increased membrane permeability. 6 Membrane perturbation by telavancin was dependent on its binding to peptidoglycan precursors, indicating selectivity for bacterial cells. 6 Following clinical success in Phase 2 studies in patients with complicated skin and skin structure infections (csssis; also called complicated skin and soft tissue infections), 7,8 telavancin is currently being evaluated by regulatory authorities in the USA, Canada and Europe for its safety and efficacy in the treatment of csssi. Patient enrolment has also been completed for two Phase 3 trials for the treatment of hospital-acquired pneumonia. The objective of the current surveillance study was to provide a prospective assessment of the in vitro activity of telavancin against a large and diverse collection of Gram-positive clinical isolates from Europe and Israel. This is the first prospective surveillance study of telavancin in these geographic areas. Materials and methods In total, 36 community, teaching and university hospital laboratories in 14 European countries (Belgium, Croatia, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Portugal, Slovakia, Spain and the UK) and Israel collected isolates between October 2004 and December Each laboratory was asked to submit 80 consecutive non-duplicate isolates of clinically relevant Gram-positive pathogens from lower respiratory tract, upper respiratory tract (Streptococcus pneumoniae only), skin and skin structure (non-s. pneumoniae only), wound (non-s. pneumoniae only) and blood specimens. The goal was to obtain 45 S. aureus, 5 coagulase-negative staphylococci (CoNS), 10 Enterococcus faecalis, 10 Enterococcus faecium, 5 S. pneumoniae and 5 other streptococci per centre. Isolates were collected from adult and paediatric patients and from both inpatients (including those in intensive care units) and outpatients. All isolates were transported to a central laboratory (Eurofins Medinet, Inc., Herndon, VA, USA) for re-identification and susceptibility testing. Susceptibility testing of telavancin and comparators was performed using the broth microdilution method in accordance with the CLSI (formerly NCCLS) guidelines 9 and microtitre trays were prepared by TREK Diagnostics (Cleveland, OH, USA). Telavancin was supplied by Theravance, Inc. (South San Francisco, CA, USA). The quality control strains E. faecalis ATCC 29212, E. faecalis ATCC 51299, S. aureus ATCC and S. pneumoniae ATCC were tested in parallel, 9 and results were required to meet the quality control limits specified by CLSI. 10 Categorical interpretation of susceptible, intermediate or resistant were applied to the test results using the 2005 CLSI criteria, 10 where applicable. Results Clinical isolates In total, 3206 isolates were collected. The isolates included 1785 S. aureus, 236 CoNS, 450 E. faecalis, 362 E. faecium, 179 S. pneumoniae, 67 viridans group streptococci, 54 Streptococcus pyogenes, 48Streptococcus agalactiae and 25 other b-haemolytic streptococci (groups C, G or F). The numbers of isolates collected from each country ranged from 64 (Poland) to 569 (Spain); the proportions of S. aureus isolates from each country ranged from 51% (Belgium) to 69% (Poland) [median: 57% (Greece)]. Most of the S. pneumoniae isolates (67%) were from the upper or lower respiratory tract. Most of the other organisms were from skin and skin structure infections (including wounds) or from blood (50% and 34% of other organisms, respectively). Nearly one-third (30%) of the S. aureus and 75% of the CoNS were methicillin-resistant (MR). Among the MRSA and MRCoNS, respectively, 93% and 68% were also resistant to ciprofloxacin, 55% and 44% to clindamycin, 38% and 58% to gentamicin and 3% and 51% to co-trimoxazole. Vancomycin resistance was seen in 22% of the E. faecium and 5% of the E. faecalis isolates; most of the resistant isolates expressed the VanA phenotype (i.e. resistance to teicoplanin). More than 40% of the enterococci had high-level resistance to streptomycin and gentamicin, and.80% of the E. faecium isolates were ampicillin-resistant. Among S. pneumoniae isolates, 16% were resistant to penicillin and 31% were resistant to multiple drugs. Of the penicillin-resistant pneumococci, 68% to clindamycin, 89% to erythromycin, 57% to tetracycline and 82% to co-trimoxazole. Among b-haemolytic and viridans group streptococci, 20% and 43%, respectively, were non-susceptible to erythromycin and the rate of resistance to tetracycline was also high in these organisms (20% to.40%). Susceptibility to telavancin Telavancin had potent in vitro activity against staphylococcal, streptococcal and enterococcal isolates (Table 1). Its activity against S. aureus was similar for methicillin-susceptible S. aureus (MSSA) and MRSA isolates; the MIC 90 values were 0.25 and 0.5 mg/l, respectively. Only 8/1238 isolates of MSSA (0.6%) and 16/547 isolates of MRSA (2.9%) were found to have the highest MIC values observed (1 mg/l). Similarly, the telavancin MIC 90 values for methicillin-susceptible and MRCoNS were 0.25 and 0.5 mg/l, respectively (Table 1). The MIC 90 values of vancomycin, teicoplanin, daptomycin, linezolid and quinupristin/dalfopristin for MSSA and MRSA were all higher than those values of telavancin; against the CoNS, the MIC 90 values of vancomycin, teicoplanin and linezolid were higher than those values of telavancin. Among the staphylococci collected, there were three S. aureus and four CoNS isolates that were non-susceptible to either daptomycin or linezolid; the telavancin MIC values for these strains ranged from 0.12 to 1 mg/l (Table 2). Table 1 also shows the MICs (MIC 50, MIC 90 and range) of telavancin and selected comparators for vancomycin-susceptible enterococci (VSE) and VRE (VanA). Telavancin MICs ranged from 0.03 to 1.0 mg/l for VSE; the MIC 90 values were 0.5 and 0.25 mg/l, respectively, for vancomycin-susceptible E. faecalis and E. faecium, which were comparable with those of teicoplanin and somewhat lower than those of vancomycin, daptomycin and linezolid. Only 18/426 isolates of vancomycin-susceptible E. faecalis (4.2%) and 3/276 isolates of vancomycin-susceptible E. faecium (1.1%) were found to have the highest MIC values observed (1 mg/l). Against VanA VRE isolates (characterized as being resistant to both vancomycin and teicoplanin), the telavancin MIC values were higher (0.5 8 mg/l) than for VSE strains, although considerably lower than those of teicoplanin (MIC 90 values.128 mg/l) and vancomycin (MIC 90 values 512 mg/l) for the VanA strains. Against seven VanB (teicoplanin-susceptible and vancomycin-resistant) isolates, the MIC values of telavancin ranged from 0.12 to 2 mg/l, comparable with the MIC values of teicoplanin, daptomycin and 117
3 Draghi et al. Table 1. Activity of telavancin and selected comparators against Gram-positive clinical isolates from Europe and Israel MIC (mg/l) Organism (no. tested) Agent range 50% 90% S. aureus, methicillin-susceptible (1238) telavancin vancomycin teicoplanin linezolid daptomycin 0.03 to quinupristin/dalfopristin gentamicin 0.06 to co-trimoxazole a 0.5 to S. aureus, methicillin-resistant (547) telavancin vancomycin teicoplanin linezolid 0.5 to daptomycin 0.25 to quinupristin/dalfopristin 0.12 to gentamicin 0.12 to co-trimoxazole a 0.5 to Coagulase-negative staphylococci, b methicillin-susceptible (60) telavancin vancomycin teicoplanin linezolid daptomycin quinupristin/dalfopristin Coagulase-negative staphylococci, b methicillin-resistant (176) telavancin vancomycin teicoplanin linezolid 0.5 to daptomycin 0.12 to quinupristin/dalfopristin 0.12 to E. faecalis, vancomycin-susceptible (426) telavancin vancomycin teicoplanin linezolid daptomycin quinupristin/dalfopristin ampicillin E. faecalis, vancomycin-resistant (VanA) (23) telavancin vancomycin 256 to teicoplanin 32 to linezolid daptomycin quinupristin/dalfopristin ampicillin E. faecium, vancomycin-susceptible (276) telavancin vancomycin teicoplanin linezolid daptomycin quinupristin/dalfopristin ampicillin 0.25 to E. faecium, vancomycin-resistant (VanA) (73) telavancin vancomycin 64 to teicoplanin 32 to linezolid Continued 118
4 In vitro activity of telavancin against European and Israeli isolates Table 1. Continued Organism (no. tested) Agent MIC (mg/l) range 50% 90% daptomycin quinupristin/dalfopristin ampicillin 8 to S. pyogenes (54) telavancin vancomycin penicillin linezolid daptomycin levofloxacin co-trimoxazole a S. agalactiae (48) telavancin vancomycin penicillin levofloxacin linezolid daptomycin co-trimoxazole a 0.06 to Streptococcus spp., groups C, F and G (25) telavancin vancomycin penicillin levofloxacin erythromycin to linezolid daptomycin co-trimoxazole a Streptococcus spp., viridans group (67) telavancin vancomycin penicillin 0.06 to levofloxacin 0.25 to linezolid daptomycin 0.03 to co-trimoxazole a 0.06 to S. pneumoniae, penicillin-susceptible (125) telavancin vancomycin penicillin levofloxacin 0.25 to linezolid co-trimoxazole a 0.06 to tetracycline 0.06 to S. pneumoniae, penicillin-non-susceptible c (54) telavancin vancomycin penicillin 0.12 to erythromycin 0.03 to levofloxacin linezolid co-trimoxazole a 0.06 to tetracycline 0.06 to a MICs expressed as concentration of trimethoprim. b Includes S. capitis (5), S. cohnii (1), S. epidermidis (130), S. haemolyticus (25), S. hominis (9), S. saprophyticus (2), S. simulans (5), S. warneri (6), S. xylosus (3) and unspeciated (50). c Includes penicillin-intermediate and -resistant isolates. 119
5 Draghi et al. Table 2. Activity of telavancin against selected Gram-positive clinical isolates from Europe and Israel not susceptible to daptomycin and/or linezolid MIC (mg/l) Organism Phenotype ID number telavancin vancomycin linezolid daptomycin S. aureus DAP NS S. aureus DAP NS S. aureus LZD NS CoNS (non-speciated) DAP NS CoNS (non-speciated) DAP NS S. epidermidis LZD NS S. epidermidis LZD NS E. faecium DAP NS E. faecium DAP NS ID, identification; DAP, daptomycin; NS, non-susceptible; LZD, linezolid; CoNS, coagulase-negative staphylococci. linezolid (data not shown). When all VSE and VRE isolates are considered together, the MIC distribution of telavancin is bimodal. This is illustrated in Figure 1, which also demonstrates that the second mode is accounted for by the MIC distribution for vancomycin-resistant isolates. Among the enterococci collected, two E. faecium isolates were non-susceptible to daptomycin; the telavancin MICs for these strains were both 0.12 mg/l (Table 2). Table 1 also illustrates the MICs of telavancin and comparators for streptococci. Among all agents tested, telavancin had the greatest potency against S. pneumoniae, with an MIC 90 of 0.03 mg/l, regardless of resistance to penicillin or other agents. Telavancin demonstrated consistently potent activity against b-haemolytic streptococci (MIC mg/l) and viridans group streptococci (MIC mg/l), regardless of their susceptibility to erythromycin. Vancomycin, levofloxacin, linezolid and daptomycin all demonstrated less potent activity against the b-haemolytic and viridans group streptococci relative to telavancin. The MIC 90 values of penicillin for the b-haemolytic streptococci were 0.06 mg/l; 25% of the viridans group streptococci were resistant to or had intermediate susceptibility to penicillin. Among other comparators, clindamycin and telithromycin were most affected by susceptibility to erythromycin (data not shown). Discussion In this report, we describe the results of a large multinational surveillance initiative specifically designed to provide a benchmark for the activity of telavancin. This was the first prospective surveillance study of this new agent in European countries and Israel. More than 3000 Gram-positive organisms were collected from diverse geographic and demographic environments to obtain a robust, representative sample of contemporary isolates. The activity of telavancin was assessed in the context of other Gram-positive agents and resistance phenotypes. We noted that resistance to established antimicrobial agents among the isolates was consistent with rates reported in previous European and international studies Importantly, the activity of telavancin was similar to that previously reported in smaller, retrospective surveillance studies. 1 4 Figure 1. Telavancin MIC distribution against enterococci (n ¼ 812). Black bars, all enterococci; grey bars, vancomycin-resistant isolates of the VanA (n ¼ 96) and VanB (n ¼ 7) phenotype. Telavancin exhibited potent in vitro activity against all staphylococcal isolates tested, regardless of resistance to other antimicrobial classes. Among the comparators, only co-trimoxazole had equivalent or lower MIC 90 values (0.5 mg/l) for S. aureus; however, a small amount of resistance to this agent (3%) was seen. In particular, the MIC 90 values of telavancin against MRSA and MRCoNS were lower than the MIC 90 values of currently available glycopeptides (vancomycin and teicoplanin). Against CoNS, only daptomycin and quinupristin/dalfopristin had activity comparable to that of telavancin. Based on the MIC 90 values, telavancin was 4-fold more active as vancomycin against Van-S enterococci. Although it was somewhat less active against VanA strains, the telavancin MIC 90 values were at least 16-fold lower than those of teicoplanin and 64-fold lower than those of vancomycin against these isolates. The potency of telavancin against VanA strains was comparable to that of non-glycopeptide agents such as linezolid and daptomycin and to that of quinupristin/dalfopristin against VanA E. faecium, but less potent than linezolid and daptomycin against VanA E. faecalis. Isolates with resistance to the most recent and highly active Gram-positive agents, linezolid and daptomycin, though 120
6 In vitro activity of telavancin against European and Israeli isolates infrequently encountered, are of significant clinical interest. As shown in this study, no alteration in the in vitro activity of telavancin was observed against the few linezolid non-susceptible isolates (S. aureus and S. epidermidis) or daptomycin nonsusceptible isolates (S. aureus, CoNS and E. faecium) encountered in this study. Telavancin demonstrated very potent and consistent antistreptococcal activity, greater than the activity observed with most of the comparators, against all species and resistance phenotypes. In particular, the MIC 90 value of telavancin was 0.03 mg/l for isolates of S. pneumoniae that were not susceptible to penicillin, which was considerably lower than those of all comparators. Among the agents tested, only penicillin showed comparable activity to telavancin against the b-haemolytic streptococci. In conclusion, telavancin demonstrated potent in vitro activity against contemporary Gram-positive clinical isolates from Europe and Israel. The activity of telavancin was not affected by resistance to other classes of antibiotics, including the new lipopeptide and oxazolidinone class agents daptomycin and linezolid, respectively. As clinical development of telavancin continues, this first prospective surveillance study will serve as a useful benchmark. Funding This study was funded by Theravance, Inc., 901 Gateway Boulevard, South San Francisco, CA, USA. Editorial assistance was provided by Matthew Smith, PhD, and funded by Astellas Pharma, Inc. Transparency declarations D. C. D., C. T., C. P. and D. F. S. are employees of Eurofins Medinet, Inc., which received funding from Theravance, Inc. D. C. D., C. T. and C. P. do not own stock or options in any company involved in the study. D. F. S. owns stock in Eurofins Medinet, Inc. B. M. B. and K. M. K. are employees of, and own stock and options for, Theravance, Inc. References 1. Goldstein EJ, Citron DM, Merriam CV et al. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 2004; 48: King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004; 53: Pace JL, Krause K, Johnston D et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: Jansen WT, Verel A, Verhoef J et al. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother 2007; 51: Pace JL, Judice JK. Telavancin (Theravance). Curr Opin Investig Drugs 2005; 6: Higgins DL, Chang R, Debabov DV et al.; FAST Investigator Group. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: Stryjewski ME, O Riordan WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40: Stryjewski ME, Chu VH, O Riordan WD et al. for the FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by grampositive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50: National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing Fifteenth Informational Supplement: M100-S15. CLSI, Wayne, PA, USA, Draghi DC, Sheehan DJ, Hogan P et al. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 Surveillance Program. Antimicrob Agents Chemother 2005; 49: Diekema DJ, BootsMiller BJ, Vaughn TE et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004; 38: Karlowsky JA, Thornsberry C, Jones ME et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program ( ). Clin Infect Dis 2003; 36: National Nosocomial Infections Surveillance (NNIS) System Report data summary from January 1992 through June 2003 issued August Am J Infect Control 2003; 31: Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database USA. Clin Infect Dis 1999; 29: Jones ME, Karlowsky JA, Draghi DC et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22: Watters AA, Jones RN, Leeds JA et al. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report ( ). J Antimicrob Chemother 2006; 57: Sader HS, Streit JM, Fritsche TR et al. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme ( ). Clin Microbiol Infect 2006; 12: Ross JE, Fritsche TR, Sader HS et al. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents 2007; 29:
In vitro Activity Evaluation of Telavancin against a Contemporary Worldwide Collection of Staphylococcus. aureus. Rodrigo E. Mendes, Ph.D.
AAC Accepts, published online ahead of print on 12 April 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00301-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationDalbavancin, enterococci, Gram-positive cocci, Latin America, staphylococci, streptococci
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01051.x Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres A. C. Gales 1, H. S. Sader 1,2
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01550.x Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002 2004)
More informationActivity of Linezolid Tested Against Uncommonly Isolated Gram-positive ACCEPTED
AAC Accepts, published online ahead of print on 8 January 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01496-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationZyvox w Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years ( )
J Antimicrob Chemother 2014; 69: 1582 1588 doi:10.1093/jac/dkt541 Advance Access publication 26 January 2014 Zyvox w Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationAntimicrobial Activity of Linezolid Against Gram-Positive Cocci Isolated in Brazil
BJID 2001; 5 (August) 171 Antimicrobial Activity of Linezolid Against Gram-Positive Cocci Isolated in Brazil Helio S. Sader, Ana C. Gales and Ronald N. Jones Special Clinical Microbiology Laboratory, Division
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationSUPPLEMENT ARTICLE. S114 CID 2001:32 (Suppl 2) Diekema et al.
SUPPLEMENT ARTICLE Survey of Infections Due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe,
More informationReceived 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationANTIMICROBIAL SUSCEPTIBILITY CONTEMPORARY SUSCEPTIBILITY TESTS AND TREATMENTS FOR VRE INFECTIONS
TREATMENTS FOR VRE INFECTIONS Sample ES-01 (2015) was a simulated blood culture isolate from a patient with associated clinical symptoms (pure culture). Participants were requested to identify any potential
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationANTIMICROBIAL SUSCEPTIBILITY DETECTION OF ELEVATED MICs TO PENICILLINS IN β- HAEMOLYTIC STREPTOCOCCI
HAEMOLYTIC STREPTOCOCCI This specimen was designated as a sample from a skin wound that was to be cultured, identified to species level and susceptibility tested [1-3]. The culture contained a Streptococcus
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationIn Vitro Activities of the Novel Cephalosporin LB against Multidrug-Resistant Staphylococci and Streptococci
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2004, p. 53 62 Vol. 48, No. 1 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.1.53 62.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationJasmine M. Chaitram, 1,2 * Laura A. Jevitt, 1,2 Sara Lary, 1,2 Fred C. Tenover, 1,2 and The WHO Antimicrobial Resistance Group 3,4
JOURNAL OF CLINICAL MICROBIOLOGY, June 2003, p. 2372 2377 Vol. 41, No. 6 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.6.2372 2377.2003 The World Health Organization s External Quality Assurance System Proficiency
More informationOriginal Article. Suwanna Trakulsomboon, Ph.D., Visanu Thamlikitkul, M.D.
Original Article Vol. 25 No. 2 In vitro activity of daptomycin against MRSA:Trakulsomboon S & Thamlikitkul V. 57 In Vitro Activity of Daptomycin against Methicillin- Resistant Staphylococcus aureus (MRSA)
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationANTIMICROBIAL SUSCEPTIBILITY VANCOMYCIN RESISTANCE IN AN UNCOMMON ENTEROCOCCAL SPECIES
ENTEROCOCCAL SPECIES Sample ES-02 was a simulated blood culture isolate from a patient with symptoms of sepsis. Participants were asked to identify any potential pathogen and to perform susceptibility
More informationR. M. Alden Research Laboratory, Santa Monica, California 90404, 1 and David Geffen School of Medicine at UCLA, Los Angeles, California
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2006, p. 2875 2879 Vol. 50, No. 8 0066-4804/06/$08.00 0 doi:10.1128/aac.00286-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. In Vitro
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationPrevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002
University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 5-10-2004 Prevalence and antimicrobial susceptibilities of bacteria isolated from
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationSTAPHYLOCOCCI: KEY AST CHALLENGES
Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationExploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent
Supplementary materials Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent Shankar Thangamani 1, Haroon Mohammad 1, Mostafa Abushahba 1, Maha Hamed 1, Tiago Sobreira
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationTest results: characterising the antimicrobial activity of daptomycin B. Wiedemann
REVIEW Test results: characterising the antimicrobial activity of daptomycin B. Wiedemann University of Bonn, Bonn, Germany ABSTRACT Daptomycin is the first in a new class of antibiotics, the cyclic lipopeptides.
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationComparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme,
European Journal of Clinical Microbiology & Infectious Diseases (2018) 37:1653 1659 https://doi.org/10.1007/s10096-018-3295-6 ORIGINAL ARTICLE Comparative activity of ceftobiprole against coagulase-negative
More informationOver the past several decades, the frequency of. Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years. Ronald N.
Resistance Patterns Among Nosocomial Pathogens* Trends Over the Past Few Years Ronald N. Jones, MD Multiple surveillance studies have demonstrated that resistance among prevalent pathogens is increasing
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationThe new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining?
S. aureus: what do we need to know (and to do) in 2007? The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining? Françoise Van Bambeke Unité de Pharmacologie
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationWhat is the problem? Latest data on antibiotic resistance
European Antibiotic Awareness Day 2009 What is the problem? Latest data on antibiotic resistance Zsuzsanna Jakab, ECDC Director Launch Seminar for EAAD Stockholm, 18 November 2009 Fluoroquinolone-resistant
More informationEpidemiology and Microbiology of Surgical Wound Infections
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2000, p. 918 922 Vol. 38, No. 2 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Epidemiology and Microbiology of Surgical
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationOver 40 Posters/Abstracts in Support of TREK Presented at the 2004 ECCMID
Over 40 Posters/Abstracts in Support of TREK Presented at the ECCMID This was our best ECCMID ever for TREK presentations! The following posters and abstracts were in support of TREK products! Sensititre
More informationTelavancin: A Review of its Use in Treating Gram-Positive Infections
Clinical Medicine Reviews in Therapeutics Expert Review Telavancin: A Review of its Use in Treating Gram-Positive Infections Sian V. Coggle 1 and M. Estée Török 2 1 Cambridge University ospitals S Foundation
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationAAC Revised. Activity of a Novel Cyclic Lipopeptide, CB-183,315 Against Resistant Clostridium difficile
AAC Accepts, published online ahead of print on 5 March 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.06257-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 AAC06257-11
More informationand Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA
Journal of Antimicrobial Chemotherapy (2004) 54, Suppl. S1, i7 i15 DOI: 10.1093/jac/dkh313 JAC Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationANTIBIOTICS IN PLASMA
by LC/MS Code LC79010 (Daptomycin, Vancomycin, Streptomycin, Linezolid, Levofloxacin, Ciprofloxacin, Gentamicin, Amikacin, Teicoplanin) INTRODUCTION Technically it defines "antibiotic" a substance of natural
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationBJID 2001; 5 (February) 21
BJID 2001; 5 (February) 21 Antimicrobial Susceptibility of Quinupristin/Dalfopristin Tested Against Gram-Positive Cocci From Latin America: Results from the Global SMART (GSMART) Surveillance Study Helio
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationEffect of dalbavancin on the normal intestinal microflora
Journal of Antimicrobial Chemotherapy (00), 1 doi:10.109/jac/dkl1 Advance Access publication 1 July 00 Effect of dalbavancin on the normal intestinal microflora Carl Erik Nord*, Gundars Rasmanis and Elisabeth
More informationESCMID Online Lecture Library. by author
ESCMID Postgraduate Technical Workshop Antimicrobial susceptibility testing and surveillance of resistance in Gram-positive cocci: laboratory to clinic Current epidemiology of invasive enterococci in Europe
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationNon-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland,
Journal of Antimicrobial Chemotherapy (2008) 62, Suppl. 2, ii65 ii74 doi:10.1093/jac/dkn353 Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001 06 Russell Hope 1
More informationComparative Antimicrobial Activities of Linezolid and Vancomycin against Gram-Positive Clinical Isolates from Hospitals in Kuwait
Original Paper Med Principles Pract 2001;10:177 181 Received: June 24, 2001 Revised: September 29, 2001 Comparative Antimicrobial Activities of Linezolid and Vancomycin against Gram-Positive Clinical Isolates
More informationSURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS
SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS Adrienn Hanczvikkel 1, András Vígh 2, Ákos Tóth 3,4 1 Óbuda University, Budapest,
More informationSusceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System
Polish Journal of Microbiology 2005, Vol. 54, No 4, 311 316 Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System EL BIETA STEFANIUK*, AGNIESZKA MRÓWKA
More informationSurveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens
Surveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens Dr Pat Mitchell R & I Manager Production Stewardship APL CDC Conference, Melbourne June 2017 Dr Kylie Hewson
More informationUltrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2009, p. 800 804 Vol. 53, No. 2 0066-4804/09/$08.00 0 doi:10.1128/aac.00603-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Ultrastructural
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationUNDERSTANDING THE ANTIBIOGRAM
UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe
More informationEvolution of antibiotic resistance. October 10, 2005
Evolution of antibiotic resistance October 10, 2005 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationCritical impact of antimicrobial resistance
New Antibiotics Kurt B. Stevenson, MD, MPH Professor of Medicine and Epidemiology Division of Infectious Diseases Department of Internal Medicine The Ohio State University College of Medicine Critical
More informationMain objectives of the EURL EQAS s
EQAS Enterococci, Staphylococci and E. coli EURL workshop, April, 11 Lourdes García Migura Main objectives of the EURL EQAS s To improve the comparability of antimicrobial susceptibility testing (AST)
More informationSUPPLEMENT ARTICLE. Donald E. Low, 1 Nathan Keller, 2 Alfonso Barth, 3 and Ronald N. Jones 4
SUPPLEMENT ARTICLE Clinical Prevalence, Antimicrobial Susceptibility, and Geographic Resistance Patterns of Enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997 1999 Donald E.
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationEnterococcal PJI. Miquel Ekkelenkamp
Enterococcal PJI Miquel Ekkelenkamp Enterococci: Gram-positive and round Formerly streptococci (but really quite different) Main clinical species : E. faecalis and E. faecium Mostly opportunistic pathogen
More informationCHAPTER 1 INTRODUCTION
1 CHAPTER 1 INTRODUCTION The Staphylococci are a group of Gram-positive bacteria, 14 species are known to cause human infections but the vast majority of infections are caused by only three of them. They
More informationAerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune
Original article Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Patil P, Joshi S, Bharadwaj R. Department of Microbiology, B.J. Medical College, Pune, India. Corresponding
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union November 2012 Highlights on antibiotic consumption Antibiotic use is one of the main factors responsible for the development and
More informationGlycopeptide Resistant Enterococci (GRE) Policy IC/292/10
BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite
More informationANTIMICROBIAL SUSCEPTIBILITY CHARACTERIZING SUSCEPTIBILITY PATTERNS OF MSSA ASSOCIATED WITH SURGICAL WOUND INFECTIONS
ASSOCIATED WITH SURGICAL WOUND INFECTIONS Specimen ES-02 was designated as a "surgical wound culture" to be identified to the species level and tested for antimicrobial susceptibility. 1-4 The culture
More information